Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment

References

• WongWLSuXLiXGlobal prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysisLancet Glob Health201422e106e11625104651
   PubMed Web of Science ®Google Scholar
• PascoliniDMariottiSPGlobal estimates of visual impairment: 2010Br J Ophthalmol201296561461822133988
   PubMed Web of Science ®Google Scholar
• RofaghaSBhisitkulRBBoyerDSSeven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)Ophthalmology2013120112292229923642856
   PubMed Web of Science ®Google Scholar
• RosenfeldPJBrownDMHeierJSRanibizumab for neovascular age-related macular degenerationN Engl J Med2006355141419143117021318
   PubMed Web of Science ®Google Scholar
• BrownDMKaiserPKMichelsMRanibizumab versus verteporfin for neovascular age-related macular degenerationN Engl J Med2006355141432144417021319
   PubMed Web of Science ®Google Scholar
• MuetherPSHermannMMViebahnUKirchhofBFauserSVascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumabOphthalmology2012119102082208622920670
   PubMed Web of Science ®Google Scholar
• FunkMKarlDGeorgopoulosMNeovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumabOphthalmology2009116122393239919815292
   PubMed Web of Science ®Google Scholar
• AhnJKMoonHJChanges in aqueous vascular endothelial growth factor and pigment epithelium-derived factor after ranibizumab alone or combined with verteporfin for exudative age-related macular degenerationAm J Ophthalmol20091485e711718724
   Web of Science ®Google Scholar
• Izumi-NagaiKNagaiNOzawaYInterleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularizationAm J Pathol200717062149215817525280
   PubMed Web of Science ®Google Scholar
• HolashJDavisSPapadopoulosNVEGF-Trap: a VEGF blocker with potent antitumor effectsProc Natl Acad Sci U S A20029917113931139812177445
   PubMed Web of Science ®Google Scholar
• HeierJSBrownDMChongVIntravitreal aflibercept (VEGF trap-eye) in wet age-related macular degenerationOphthalmology2012119122537254823084240
   PubMed Web of Science ®Google Scholar
• Schmidt-ErfurthUKaiserPKKorobelnikJFIntravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studiesOphthalmology2014121119320124084500
   PubMed Web of Science ®Google Scholar
• ChoHShahCPWeberMHeierJSAflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumabBr J Ophthalmol20139781032103523766432
   PubMed Web of Science ®Google Scholar
• KumarNMarsigliaMMrejenSVisual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degenerationRetina20133381605161223549101
   PubMed Web of Science ®Google Scholar
• BakallBFolkJCBoldtHCAflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumabAm J Ophthalmol20131561152223706500
   PubMed Web of Science ®Google Scholar
• WykoffCCBrownDMMaldonadoMECroftDEAflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial)Br J Ophthalmol201498795195524518078
   PubMed Web of Science ®Google Scholar
• MillerJWSchmidt-ErfurthUSickenbergMPhotodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a Phase 1 and 2 studyArch Ophthalmol199911791161117310496388
   PubMedGoogle Scholar
• Verteporfin in Photodynamic Therapy Study GroupVerteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization – verteporfin in photodynamic therapy report 2Am J Ophthalmol2001131554156011336929
   PubMed Web of Science ®Google Scholar
• Wolf-SchnurrbuschUEBrinkmannCKBergerLWolfSEffects of combination therapy with verteporfin photodynamic therapy and ranibizumab in patients with age-related macular degenerationActa Ophthalmol201189658559019878113
   PubMed Web of Science ®Google Scholar
• SpielbergLLeysATreatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 yearsGraefes Arch Clin Exp Ophthalmol2010248794395620204659
   PubMed Web of Science ®Google Scholar
• Schmidt-ErfurthUWolfSPROTECT Study GroupSame-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degenerationBr J Ophthalmol200892121628163518772178
   PubMed Web of Science ®Google Scholar
• TozerKRChongLSaddaSRRescue Therapy With Combined Anti-vegf And Pdt For Refractory AMDInvestigative Ophthalmology & Visual Science20115214167120926815
   PubMed Web of Science ®Google Scholar
• EghøjMSSørensenTLTachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumabBr J Ophthalmol2012961212321733918
   PubMed Web of Science ®Google Scholar
• BinderSLoss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?20121222157632
   PubMedGoogle Scholar
• GrossniklausHELingJXWallaceTMMacrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularizationMol Vis2002811912611979237
   PubMed Web of Science ®Google Scholar
• HermannMMvan AstenFMuetherPSPolymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degenerationOphthalmology2014121490591024365177
   PubMed Web of Science ®Google Scholar
• CoxNJWarburtonJArmstrongAHollidayVJFitting concentration and load rating curves with generalized linear modelsEarth Surf Process Landf20083312539
   Web of Science ®Google Scholar
• RobertCPMonte Carlo MethodsWileyOnline Library2004
   Google Scholar
• MccaffreyDFRidgewayGMorralARPropensity score estimation with boosted regression for evaluating causal effects in observational studiesPsychol Methods20049440342515598095
   PubMed Web of Science ®Google Scholar
• BurgetteLGriffinBAMccaffreyDPropensity scores for multiple treatments: a tutorial for the mnps function in the twang packageR Package Rand Corporation2016
   Google Scholar
• Díaz-UriarteRAlvarez de AndrésSGene selection and classification of microarray data using random forestBMC Bioinformatics20067316398926
   PubMed Web of Science ®Google Scholar
• RakicJMLambertVDevyLPlacental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularizationInvest Ophthalmol Vis Sci20034473186319312824270
   PubMed Web of Science ®Google Scholar
• FerraraNDamicoLShamsNLowmanHKimRDevelopment of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degenerationRetina200626885987017031284
   PubMed Web of Science ®Google Scholar
• ChenYWiesmannCFuhGSelection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigenJ Mol Biol1999293486588110543973
   PubMed Web of Science ®Google Scholar
• BlackhurstDWMaguireMGReproducibility of refraction and visual acuity measurement under a standard protocol. The Macular Photocoagulation Study GroupRetina1989931631692480626
   PubMed Web of Science ®Google Scholar
• MuetherPSHoersterRHermannMMKirchhofBFauserSLong-term effects of ranibizumab treatment delay in neovascular age-related macular degenerationGraefes Arch Clin Exp Ophthalmol2013251245345822573410
   PubMed Web of Science ®Google Scholar
• de MassougnesSDiraniAAmbresinAPigment epithelial detachment response to aflibercept in neovascular age-related macular degeneration refractory to ranibizumab: time course and drug effectsRetina201636588188827115852
   PubMed Web of Science ®Google Scholar
• PeschonJJMorrisseyPJGrabsteinKHEarly lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient miceJ Exp Med19941805195519607964471
   PubMed Web of Science ®Google Scholar
• TanJTDudlELeRoyEIL-7 is critical for homeostatic proliferation and survival of naive T cellsProc Natl Acad Sci U S A200198158732873711447288
   PubMed Web of Science ®Google Scholar
• RosenbergSASportèsCAhmadzadehMIL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cellsJ Immunother200629331331916699374
   PubMed Web of Science ®Google Scholar
• von Freeden-JeffryUDavidsonNWilerRFortMBurdachSMurrayRIL-7 deficiency prevents development of a non-T cell non-B cell-mediated colitisJ Immunol199816110567356809820548
   PubMed Web of Science ®Google Scholar
• SakuraiETaguchiHAnandATargeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularizationInvest Ophthalmol Vis Sci20034462743274912766082
   PubMed Web of Science ®Google Scholar
• DennigDLacerdaJYanYGasparettoCO’ReillyRJICAM-1 (CD54) expression on B lymphocytes is associated with their costimulatory function and can be increased by coactivation with IL-1 and IL-7Cell Immunol199415624144237912996
   PubMed Web of Science ®Google Scholar
• FauserSViebahnUMuetherPSIntraocular and systemic inflammation-related cytokines during one year of ranibizumab treatment for neovascular age-related macular degenerationActa Ophthalmol201593873473826016605
   PubMed Web of Science ®Google Scholar
• HigginsGTWangJHDockeryPClearyPERedmondHPInduction of angiogenic cytokine expression in cultured RPE by ingestion of oxidized photoreceptor outer segmentsInvest Ophthalmol Vis Sci20034441775178212657621
   PubMed Web of Science ®Google Scholar
• Schlötzer-SchrehardtUViestenzANaumannGOLaquaHMichelsSSchmidt-ErfurthUDose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyesGraefes Arch Clin Exp Ophthalmol2002240974875712271373
   PubMed Web of Science ®Google Scholar
• BresslerNMTreatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study GroupPhotodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2Arch Ophthalmol2001119219820711176980
   PubMed Web of Science ®Google Scholar
• ParkHYKwonHMLimHJPotential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitroExp Mol Med20013329510211460888
   PubMed Web of Science ®Google Scholar
• BouloumiéADrexlerHCLafontanMBusseRLeptin, the product of Ob gene, promotes angiogenesisCirc Res19988310105910669815153
   PubMed Web of Science ®Google Scholar
• CuiJZHornanDPotterMJThe role of leptin in choroidal neovascularizationAm J Ophthalmol2001132579279411704049
   PubMed Web of Science ®Google Scholar
• BarnesTCAndersonMEMootsRJThe many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosisInt J Rheumatol20112011721608621941555
   PubMedGoogle Scholar
• RohMIKimHSSongJHLimJBKohHJKwonOWConcentration of cytokines in the aqueous humor of patients with naive, recurrent and regressed CNV associated with and after bevacizumab treatmentRetina200929452352919262441
   PubMed Web of Science ®Google Scholar
• Izumi-NagaiKNagaiNOzawaYInterleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularizationAm J Pathol200717062149215817525280
   PubMed Web of Science ®Google Scholar
• LanzettaPGroup FSCombination intravitreal ranibizumab 0.5 mg and verteporfin PDT versus verteporfin PDT alone in the FOCUS study of neovascular age-related macular degeneration (AMD)Invest Ophthalmol Vis Sci2007482869
   Google Scholar
• LarsenBDavisMMudvariSCombination Lucentis and Ocular Photodynamic Therapy with Visudyne, with Evaluation-Based Retreatments (CLOVER) TrialInvest Ophthalmol Vis Sci201051902
   Web of Science ®Google Scholar
• LashkariKHiroseTYazdanyJMcMeelJWKazlauskasARahimiNVascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurityAm J Pathol200015641337134410751359
   PubMed Web of Science ®Google Scholar
• JinMChenYHeSRyanSJHintonDRHepatocyte growth factor and its role in the pathogenesis of retinal detachmentInvest Ophthalmol Vis Sci200445132332914691191
   PubMed Web of Science ®Google Scholar
• NaldiniLVignaENarsimhanRPHepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-METOncogene1991645015041827664
   PubMed Web of Science ®Google Scholar
• GriersonIHeathcoteLHiscottPHepatocyte growth factor/scatter factor in the eyeProg Retin Eye Res200019677980211029554
   PubMed Web of Science ®Google Scholar